欧州の急性期シンドロミック検査市場 - 分析と予測（2023年～2033年）

欧州の急性期シンドロミック検査の市場規模は、2022年に9億米ドルと評価され、2023年から2033年にかけてCAGR 8.95%で拡大し、2033年には23億2,000万米ドルに達すると予測されています。

シンドロミック・パネルのような分子診断技術は、複数の病原体を同時に検出することができます。これらの病原体は通常、同等の、あるいは重複する臨床症状を示すため、患者の管理が容易になり、特定の症状の診断がより容易になります。

感染症の早期発見に対する需要の高まりにより、欧州の急性期シンドロミック検査業界は顕著な急成長を遂げています。パンデミックの発生と感染症の流行が、この上昇に大きく寄与しています。さらに、世界の気温の上昇や、さまざまな場所で新たな感染症が発見されたことも、この産業の拡大を後押ししています。

欧州の急性期シンドロミック検査分野では、有望なヘルスケアソリューションが利用可能であり、さらなる発展が期待できます。急性期医療シンドロミック検査市場は、感染症の早期発見、治療計画、診断、モニタリングのための機器の進歩の結果として成長しています。欧州市場では、ヘルスケアインフラへの投資と先進診断技術の導入が増加しており、急性期医療シンドロミックパネル検査市場の成長をさらに後押ししています。さらに、ルーチン臨床におけるシンドロミックパネル検査の統合を促進する有利な規制やイニシアチブもあります。

当レポートでは、欧州の急性期シンドロミック検査市場について調査し、市場の概要とともに、エンドユーザー別、国別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 市場

• 製品の定義
• 包含基準と除外基準
• 市場範囲
• 調査手法

第2章 市場概要

• 概要
• 急性期治療症候群検査のワークフロー分析
• 市場のフットプリントと成長の可能性
• 将来性

第3章 業界考察

• ステークホルダーの視点（N=20）
  • 医師の認識
  • 支払者の認識
  • 投資家の認識
• 急性期治療症候群検査市場の法的および規制の枠組み
  • 北米の規制枠組み
  • 欧州の規制枠組み
  • アジア太平洋の規制枠組み
  • ラテンアメリカの規制枠組み
  • その他の地域における規制の枠組み
• 製品のベンチマーク

第4章 市場力学

• 概要
• 影響分析
• 市場促進要因
• 市場の課題
• 市場機会

第5章 欧州

• 概要
• 欧州
  • 欧州の急性期シンドロミック検査市場、エンドユーザー別
  • 欧州の急性期シンドロミック検査市場、国別

第6章 企業プロファイル

• 急性期シンドロミック検査市場参入企業
• Biocartis NV
• bioMerieux SA（BioFire Diagnostics）
• DiaSorin S.p.A（Luminex Corporation）
• Eurofins Scientific（Eurofins Viracor）
• QIAGEN N.V.
• QuantuMDx Group Ltd.
• Siemens Healthineers AG

List of Figures

• Figure 1: Acute Care Syndromic Testing Market, $Billion, 2023 and 2033
• Figure 2: History of Known Pandemics
• Figure 3: Incidence of Common Infectious Diseases in the U.S (Excluding Influenza), 2020
• Figure 4: Acute Care Syndromic Testing Market (by Disease Type), Share (%), 2022 and 2033
• Figure 5: Acute Care Syndromic Testing Market (by Target), Share (%), 2022 and 2033
• Figure 6: Share of Acute Care Syndromic Testing Market (by Region), 2022
• Figure 7: Share of Key Developments and Strategies, January 2020-June 2023
• Figure 8: Acute Care Syndromic Testing Market (by Company), Share (%), 2022
• Figure 9: Acute Care Syndromic Testing Market: Research Methodology
• Figure 10: Primary Research Methodology
• Figure 11: Bottom-Up Approach (Segment-Wise Analysis)
• Figure 12: Top-Down Approach (Segment-Wise Analysis)
• Figure 13: Acute Care Syndromic Testing Workflow
• Figure 14: Acute Care Syndromic Testing Market, $Billion, 2022-2033
• Figure 15: Physician's Perception on the Factors Affecting the Adoption of Acute Care Syndromic Testing
• Figure 16: Acute Care Syndromic Testing Market Dynamics
• Figure 17: Traditional Testing vs. Syndromic Testing
• Figure 18: Incidence of Common Infectious Diseases in the U.S (Excluding Influenza), 2020
• Figure 19: Incidence of Common Infectious Diseases in Germany (Excluding COVID-19), 2020
• Figure 20: Incidence of Common Infectious Diseases in China, 2020
• Figure 21: History of Known Pandemics
• Figure 22: Examples of Cost Reductions
• Figure 23: Time of Diagnosis vs. Disease Effect
• Figure 24: Syndromic Panels Reimbursement Scenario in the U.S.
• Figure 25: Syndromic Panels Reimbursement Scenario in Mexico
• Figure 26: Reduction in Antibiotics Use with Syndromic Testing
• Figure 27: Increasing Synergistic Activities of the Acute Care Syndromic Testing Market, January 2021-June 2023 (Number of Partnerships, Collaborations and Agreements)
• Figure 28: Key Mergers and Acquisitions in the Acute Care Syndromic Testing Market
• Figure 29: Acute Care Syndromic Testing Market Snapshot (by Region)
• Figure 30: Acute Care Syndromic Testing Market (by Region), $Billion, 2022-2033
• Figure 31: Europe Acute Care Syndromic Testing Market, $Billion, 2022-2033
• Figure 32: Europe Acute Care Syndromic Testing Market (by End User), $Billion, 2023-2033
• Figure 33: Europe Acute Care Syndromic Testing Market (by Country), $Million, 2022-2033
• Figure 34: Top 5 Most Common Infectious Diseases in Germany, 2020
• Figure 35: Germany Acute Care Syndromic Testing Market, $Million, 2022-2033
• Figure 36: France Acute Care Syndromic Testing Market, $Million, 2022-2033
• Figure 37: U.K. Acute Care Syndromic Testing Market, $Million, 2022-2033
• Figure 38: Italy Acute Care Syndromic Testing Market, $Million, 2022-2033
• Figure 39: Spain Acute Care Syndromic Testing Market, $Million, 2022-2033
• Figure 40: Rest-of-Europe Acute Care Syndromic Testing Market, $Million, 2022-2033
• Figure 41: Acute Care Syndromic Testing Market, Total Number of Companies Profiled
• Figure 42: Biocartis NV: Product Portfolio
• Figure 43: Biocartis NV: Overall Financials, $Million, 2020-2022
• Figure 44: Biocartis NV: R&D Expenditure, $Million, 2020-2022
• Figure 45: bioMerieux SA (BioFire Diagnostics): Product Portfolio
• Figure 46: bioMerieux SA (BioFire Diagnostics): Overall Financials, $Million, 2020-2022
• Figure 47: bioMerieux SA (BioFire Diagnostics): Revenue (by Segment), $Million, 2020-2022
• Figure 48: bioMerieux SA (BioFire Diagnostics): Revenue (by Region), $Million, 2020-2022
• Figure 49: bioMerieux SA (BioFire Diagnostics): R&D Expenditure, $Million, 2020-2022
• Figure 50: DiaSorin S.p.A (Luminex Corporation): Product Portfolio
• Figure 51: DiaSorin S.p.A (Luminex Corporation): Overall Financials, $Million, 2021 and 2022
• Figure 52: DiaSorin S.p.A (Luminex Corporation): Revenue (by Region), $Million, 2021 and 2022
• Figure 53: DiaSorin S.p.A (Luminex Corporation): R&D Expenditure, $Million, 2021 and 2022
• Figure 54: Eurofins Scientific (Eurofins Viracor): Product Portfolio
• Figure 55: Eurofins Scientific (Eurofins Viracor): Overall Financials, $Million, 2020-2022
• Figure 56: Eurofins Scientific (Eurofins Viracor): Revenue (by Segment), $Million, 2020-2022
• Figure 57: Eurofins Scientific (Eurofins Viracor): Revenue (by Region), $Million, 2020-2022
• Figure 58: QIAGEN N.V.: Product Portfolio
• Figure 59: QIAGEN N.V.: Overall Financials, $Million, 2020-2022
• Figure 60: QIAGEN N.V.: Revenue (by Segment), $Million, 2020-2022
• Figure 61: QIAGEN N.V.: Revenue (by Region), $Million, 2020-2022
• Figure 62: QIAGEN N.V.: R&D Expenditure, $Million, 2020-2022
• Figure 63: QuantuMDx Group Ltd.: Product Portfolio
• Figure 64: Siemens Healthineers AG: Product Portfolio
• Figure 65: Siemens Healthineers AG: Overall Financials, $Million, 2020-2022
• Figure 66: Siemens Healthineers AG: Revenue (by Segment), $Million, 2020-2022
• Figure 67: Siemens Healthineers AG: Revenue (by Region), $Million, 2020-2022
• Figure 68: Siemens Healthineers AG: R&D Expenditure, $Million, 2020-2022

List of Tables

• Table 1: Acute Care Syndromic Testing Product Mapping Analysis (by Disease Type)
• Table 2: Acute Care Syndromic Testing Market: Impact Analysis
• Table 3: Key Questions Answered in the Report
• Table 4: Product Benchmarking of Acute Care Syndromic Testing Panels
• Table 5: Likert Scale
• Table 6: Impact Analysis of Market Drivers
• Table 7: Impact Analysis of Market Challenges
• Table 8: Popular Assays and Their Turnaround Times
• Table 9: Acute Care Syndromic Testing Ecosystem Active Players

“The Europe Acute Care Syndromic Testing Market Expected to Reach $2.32 Billion by 2033.”

Introduction to Europe Acute Care Syndromic Testing Market

The Europe acute care syndromic testing market was valued at $0.90 billion in 2022 and is expected to reach $2.32 billion by 2033, growing at a CAGR of 8.95% between 2023 and 2033. Molecular diagnostics techniques such as syndromic panels are capable of simultaneously detecting several pathogens. These pathogens typically exhibit comparable or overlapping clinical symptomatology, making patient management easier and specific symptom diagnosis more straightforward.

Market Introduction

The increasing demand for early infectious illness identification has led to a notable surge in the acute care syndromic testing industry in Europe. The incidence of pandemics and the prevalence of infectious diseases have been major contributors to this rise. Furthermore, the expansion of the industry has been aided by the rise in global temperatures and the discovery of new infectious diseases in different places.

Promising healthcare solutions are available in the European acute care syndromic testing sector, and more developments may be possible. The acute care syndromic testing market is growing as a result of the advancement of instruments for early detection, treatment planning, diagnosis, and monitoring of infectious diseases. The Europe market is witnessing increasing investments in healthcare infrastructure and the adoption of advanced diagnostic technologies, further boosting the growth of the acute care syndromic panel testing market. Additionally, favorable regulations and initiatives promoting the integration of syndromic panel testing in routine clinical.

Market Segmentation

Segmentation 1: by End User

• Hospitals
• Clinical and Diagnostic Laboratories
• Research and Academic Institutions
• Other End Users

Segmentation 2: by Country

• Germany
• U.K.
• France
• Italy
• Spain
• Rest-of-Europe

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: The Europe acute care syndromic testing market has been extensively segmented on the basis of various categories, such as end user and Country. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Competitive Strategy: The Europe acute care syndromic testing market has numerous startups paving their way into manufacturing kits, panels, assays, and instruments and entering the market. Key players in the Europe acute care syndromic testing market analyzed and profiled in the study involve established players that offer various kinds of disease-specific panels and multiplex instruments.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and regional presence.

Some of the prominent names in this market are:

Table of Contents

1 Markets

• 1.1 Product Definition
• 1.2 Inclusion and Exclusion Criteria
• 1.3 Market Scope
  • 1.3.1 Key Questions Answered in the Report
• 1.4 Research Methodology
  • 1.4.1 Acute Care Syndromic Testing Market: Research Methodology
  • 1.4.2 Data Sources
    • 1.4.2.1 Primary Data Sources
    • 1.4.2.2 Secondary Data Sources
  • 1.4.3 Market Estimation Model
  • 1.4.4 Criteria for Company Profiling

2 Market Overview

• 2.1 Overview
• 2.2 Acute Care Syndromic Testing Workflow Analysis
• 2.3 Market Footprint and Growth Potential
• 2.4 Future Potential

3 Industry Insight

• 3.1 Stakeholder's Perspective (N=20)
  • 3.1.1 Physician's Perception
  • 3.1.2 Payor's Perception
  • 3.1.3 Investor's Perception
• 3.2 Legal and Regulatory Framework of the Acute Care Syndromic Testing Market
  • 3.2.1 Regulatory Framework in North America
    • 3.2.1.1 The U.S.
    • 3.2.1.2 Canada
  • 3.2.2 Regulatory Framework in Europe
  • 3.2.3 Regulatory Framework in Asia-Pacific
    • 3.2.3.1 Japan
    • 3.2.3.2 China
    • 3.2.3.3 India
    • 3.2.3.4 South Korea
    • 3.2.3.5 Australia
  • 3.2.4 Regulatory Framework in Latin America
    • 3.2.4.1 Brazil
    • 3.2.4.2 Mexico
  • 3.2.5 Regulatory Framework in Rest-of-the-World
    • 3.2.5.1 U.A.E.
    • 3.2.5.2 K.S.A.
• 3.3 Product Benchmarking

4 Market Dynamics

• 4.1 Overview
• 4.2 Impact Analysis
• 4.3 Market Drivers
  • 4.3.1 Faster Results Acquired with Syndromic Tests
  • 4.3.2 Increasing Incidence of Infectious Diseases
  • 4.3.3 Overall Reduced Cost of Care Due to Early Diagnosis with Syndromic Testing
  • 4.3.4 Reduced Severe Adverse Effects from Pathogens
• 4.4 Market Challenges
  • 4.4.1 Need for Better Policies with Respect to Acute Care Syndromic Test Reimbursement
  • 4.4.2 Lack of High-Complexity Testing Centres
• 4.5 Market Opportunities
  • 4.5.1 Quick Access to Treatment and Reduced Use of Antibiotics
  • 4.5.2 High Number of Synergistic Activities and Mergers and Acquisitions (M&A) Over the Past Years

5 Europe

• 5.1 Overview
• 5.2 Europe
  • 5.2.1 Europe Acute Care Syndromic Testing Market, By End User
  • 5.2.2 Europe Acute Care Syndromic Testing Market, By Country
    • 5.2.2.1 Germany
    • 5.2.2.2 France
    • 5.2.2.3 U.K.
    • 5.2.2.4 Italy
    • 5.2.2.5 Spain
    • 5.2.2.6 Rest-of-Europe

6 Company Profiles

• 6.1 Overview
• 6.2 Acute Care Syndromic Testing Ecosystem Active Players
• 6.3 Biocartis NV
  • 6.3.1 Company Overview
  • 6.3.2 Role of Biocartis NV in the Acute Care Syndromic Testing Market
  • 6.3.3 Financials
  • 6.3.4 Recent Developments
    • 6.3.4.1 Business Strategies
  • 6.3.5 Analyst Perspective
• 6.4 bioMerieux SA (BioFire Diagnostics)
  • 6.4.1 Company Overview
  • 6.4.2 Role of bioMerieux SA (BioFire Diagnostics) in the Acute Care Syndromic Testing Market
  • 6.4.3 Financials
  • 6.4.4 Recent Developments
    • 6.4.4.1 Business Strategies
  • 6.4.5 Analyst Perspective
• 6.5 DiaSorin S.p.A (Luminex Corporation)
  • 6.5.1 Company Overview
  • 6.5.2 Role of DiaSorin S.p.A (Luminex Corporation) in the Acute Care Syndromic Testing Market
  • 6.5.3 Financials
  • 6.5.4 Recent Developments
    • 6.5.4.1 Corporate Strategies
    • 6.5.4.2 Business Strategies
  • 6.5.5 Analyst Perspective
• 6.6 Eurofins Scientific (Eurofins Viracor)
  • 6.6.1 Company Overview
  • 6.6.2 Role of Eurofins Scientific (Eurofins Viracor) in the Acute Care Syndromic Testing Market
  • 6.6.3 Financials
  • 6.6.4 Recent Developments
    • 6.6.4.1 Business Strategies
  • 6.6.5 Analyst Perspective
• 6.7 QIAGEN N.V.
  • 6.7.1 Company Overview
  • 6.7.2 Role of QIAGEN N.V. in the Acute Care Syndromic Testing Market
  • 6.7.3 Financials
  • 6.7.4 Recent Developments
    • 6.7.4.1 Business Strategies
  • 6.7.5 Analyst Perspective
• 6.8 QuantuMDx Group Ltd.
  • 6.8.1 Company Overview
  • 6.8.2 Role of QuantuMDx Group Ltd. in the Acute Care Syndromic Testing Market
  • 6.8.3 Recent Developments
    • 6.8.3.1 Corporate Strategies
    • 6.8.3.2 Business Strategies
  • 6.8.4 Analyst Perspective
• 6.9 Siemens Healthineers AG
  • 6.9.1 Company Overview
  • 6.9.2 Role of Siemens Healthineers AG in the Acute Care Syndromic Testing Market
  • 6.9.3 Financials
  • 6.9.4 Analyst Perspective